Journal article icon

Journal article

Targeted IL‐4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis

Abstract:

F8‐IL‐4 is a recently developed immunocytokine that delivers IL‐4 to sites of inflammation by targeting the neovasculature. We previously reported that F8‐IL‐4, in combination with dexamethasone (DXM), provides a durable therapy in mice with collagen‐induced arthritis (CIA). Therefore, the objective of this study was to identify the mechanism by which IL‐4 and DXM combination therapy provides long‐lasting disease remission. F8‐IL‐4 alone attenuated inflammation in CIA and this was associated ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/eji.201546221

Authors


More by this author
Role:
Author
ORCID:
0000-0001-5234-7370
More from this funder
Name:
“Profiling Responder in Antibody Therapies” (PRIAT)
Publisher:
Wiley
Journal:
European Journal of Immunology More from this journal
Volume:
46
Issue:
5
Pages:
1246-1257
Publication date:
2016-03-21
Acceptance date:
2016-02-27
DOI:
EISSN:
1521-4141
ISSN:
0014-2980
Pmid:
26919786
Language:
English
Keywords:
Pubs id:
pubs:609118
UUID:
uuid:0839923d-143b-4793-847b-007613ec967d
Local pid:
pubs:609118
Source identifiers:
609118
Deposit date:
2018-05-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP